Small molecule perturbation of the CAND1-Cullin1-ubiquitin cycle stabilizes p53 and triggers Epstein-Barr virus reactivation
Open Access
- 17 July 2017
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS Pathogens
- Vol. 13 (7) , e1006517
Abstract
The chemical probe C60 efficiently triggers Epstein-Barr Virus (EBV) reactivation from latency through an unknown mechanism. Here, we identify the Cullin exchange factor CAND1 as a biochemical target of C60. We also identified CAND1 in an shRNA library screen for EBV lytic reactivation. Gene expression profiling revealed that C60 activates the p53 pathway and protein analysis revealed a strong stabilization and S15 phosphorylation of p53. C60 reduced Cullin1 association with CAND1 and led to a global accumulation of ubiquitylated substrates. C60 also stabilized the EBV immediate early protein ZTA through a Cullin-CAND1-interaction motif in the ZTA transcription activation domain. We propose that C60 perturbs the normal interaction and function of CAND1 with Cullins to promote the stabilization of substrates like ZTA and p53, leading to EBV reactivation from latency. Understanding the mechanism of action of C60 may provide new approaches for treatment of EBV associated tumors, as well as new tools to stabilize p53.Keywords
Funding Information
- National Cancer Institute (RO1 CA193624)
- National Institute of Dental and Craniofacial Research (RO1 DE017336)
- National Cancer Institute (P30 CA010815)
This publication has 52 references indexed in Scilit:
- Epstein–Barr virus: more than 50 years old and still providing surprisesNature Reviews Cancer, 2016
- Viral Carcinogenesis Beyond Malignant Transformation: EBV in the Progression of Human CancersTrends in Microbiology, 2016
- Adoptive T-Cell Immunotherapy2015
- Epstein-Barr Virus Lytic Cycle Reactivation2015
- Targeted therapy for Epstein-Barr virus-associated gastric carcinoma using low-dose gemcitabine-induced lytic activationOncotarget, 2015
- The need and challenges for development of an Epstein-Barr virus vaccineVaccine, 2013
- Theodore E. Woodward Award: development of novel, EBV-targeted therapies for EBV-positive tumors.2006
- Epstein–Barr virus: 40 years onNature Reviews Cancer, 2004
- Virally targeted therapies for EBV-associated malignanciesOncogene, 2003
- Epstein–Barr virus as a therapeutic target in Hodgkin's disease and nasopharyngeal carcinomaSeminars in Cancer Biology, 1996